Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
27.11.2017 22:37:00

Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City

SAN FRANCISCO, Nov. 27, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation will be webcast at the upcoming Piper Jaffray 29th Annual Healthcare Conference in New York City on Tuesday, November 28, 2017 at 5:10 p.m. ET. 

The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://ir.nektar.com/events.cfm. This Webcast will be available for replay until December 29, 2017.

About Nektar

Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact:

Investors
Jennifer Ruddock of Nektar Therapeutics
415-482-5585 

 

 

View original content:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-the-piper-jaffray-29th-annual-healthcare-conference-in-new-york-city-300562135.html

SOURCE Nektar Therapeutics

Analysen zu Nektar Therapeuticsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Nektar Therapeutics 1,02 7,70% Nektar Therapeutics